Article Text

Response to: ‘The role of temporal artery biopsy in patients with giant cell arteritis is debated’ by Moiseev et al
  1. Christian Dejaco1,2,
  2. Sofia Ramiro3,
  3. Christina Duftner4,
  4. Wolfgang A Schmidt5
  1. 1Department of Rheumatology and Immunology, Medical University Graz, Graz, Austria
  2. 2Department of Rheumatology, Hospital of Bruneck, Bruneck, Italy
  3. 3Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
  4. 4Department of Internal Medicine VI, Medical University Innsbruck, Innsbruck, Austria
  5. 5Medical Centre for Rheumatology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany
  1. Correspondence to Dr Christian Dejaco, Department of Rheumatology and Immunology, Medical University Graz, Graz 8036, Austria; christian.dejaco{at}

Statistics from

Moiseev et al1 underlined the main message of the new European League Against Rheumatism (EULAR) recommendations for the use of imaging in large vessel vasculitis (LVV), namely the importance of imaging as a first-line test for the diagnosis of LVV.2 The EULAR task force also emphasised that the recommendations should not be understood as a recommendation against performing temporal artery biopsy (TAB) in giant cell arteritis (GCA), rather a biopsy still has its place when there is diagnostic doubt after having performed imaging or when imaging is not available or not performed with sufficient expertise. When a diagnosis can be …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles